Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gain Therapeutics Inc
(NQ:
GANX
)
1.990
+0.150 (+8.15%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gain Therapeutics Inc
< Previous
1
2
Next >
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
September 26, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
September 19, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
August 29, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
August 08, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference
August 01, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
June 28, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
June 27, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
June 27, 2024
Data demonstrates improvement in cognitive function in GBA1 Parkinson’s disease model in addition to reversal of motor function deficits
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
June 25, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Gain Therapeutics Inc. (NASDAQ: GANX) Releases Pricing of Underwritten Public Offering, Projected to Reach $11M
June 18, 2024
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Gain Therapeutics Announces Pricing of $11.0 Million Public Offering
June 13, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces Proposed Public Offering
June 13, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024
May 30, 2024
New data demonstrating improvement of cognitive performance after treatment with GT-02287 in preclinical model of GBA1 Parkinson’s disease
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
May 14, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
April 24, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
April 08, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
April 01, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
March 26, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Present at Public Ventures Discovery Day
March 15, 2024
Gain Therapeutics’ Former CEO and current Board Member Eric Richman to participate in fireside chat hosted by Public Ventures President Lou Basenese and Aberdeen Investment Management President Jeb...
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
March 05, 2024
Data support the ability of GT-02287 to prevent several steps in the disease cascade resulting from GCase misfolding and dysfunction
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
February 27, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
February 14, 2024
Event, moderated by Hartaj Singh and Eka Gigauri of Oppenheimer & Co., will be held on Thursday, February 22, 2024 at 11:00 am EST
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
February 06, 2024
Data presented at 20th WORLDSymposium™ show progressive reversal of motor deficit and corresponding reduction of neurodegeneration biomarker NfL to level of control arm
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
February 06, 2024
Data presented at 20th WORLDSymposium™ show progressive reversal of motor deficit and corresponding reduction of neurodegeneration biomarker NfL to level of control arm
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update
January 31, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
January 02, 2024
Presentation will highlight new data of GT-02287 in preclinical models of Parkinson’s disease
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research
December 04, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model
December 01, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate in AI Driven Drug Discovery Summit
November 29, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.